{
  "version": "1",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "count": 26,
  "records": [
    {
      "slug": "5-htp",
      "version": "1",
      "displayName": "5-HTP",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "5-HTP"
      ],
      "shelfComparable": true,
      "primaryFloorId": "mood-50",
      "trialFloors": [
        {
          "id": "mood-50",
          "label": "Depression trial in Parkinson's disease (50 mg/day)",
          "presetLabel": "Meloni 2020",
          "amount": 50,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "32067288"
          ],
          "n": 25,
          "note": "50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide.",
          "effectDirection": "weak-benefit",
          "referenceKind": "single-trial",
          "funding": "not-stated"
        },
        {
          "id": "addon-300",
          "label": "Antidepressant add-on (300 mg/day)",
          "presetLabel": "Nardini 1983",
          "amount": 300,
          "frequency": "daily",
          "horizon": "28 days",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "6381336"
          ],
          "n": 26,
          "note": "300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber.",
          "effectDirection": "benefit",
          "referenceKind": "single-trial",
          "funding": "not-stated"
        },
        {
          "id": "appetite-900",
          "label": "Obesity trial (900 mg/day)",
          "presetLabel": "Cangiano 1992",
          "amount": 900,
          "frequency": "daily",
          "horizon": "two consecutive 6-wk periods",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "1384305"
          ],
          "n": 20,
          "note": "900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance.",
          "effectDirection": "weak-benefit",
          "referenceKind": "single-trial",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "5-htp-with-ssris",
        "winter-blues-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/5-htp-with-ssris/",
        "https://supplementbrief.com/winter-blues-supplements/"
      ],
      "shelf": null,
      "updatedDate": "2026-11-14",
      "dosePageUrl": "https://supplementbrief.com/dose/5-htp/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/5-htp.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/5-htp/"
    },
    {
      "slug": "ashwagandha",
      "version": "1",
      "displayName": "Ashwagandha",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Ashwagandha"
      ],
      "shelfComparable": true,
      "primaryFloorId": "chandrasekhar-300",
      "trialFloors": [
        {
          "id": "chandrasekhar-300",
          "label": "Stress and cortisol RCT (Chandrasekhar 2012)",
          "presetLabel": "Stress RCT",
          "amount": 300,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "23439798"
          ],
          "n": 64,
          "effectDirection": "benefit",
          "note": "High-concentration full-spectrum root extract, 300 mg per day for eight weeks in a randomized double-blind placebo-controlled trial of 64 adults. Serum cortisol fell significantly versus placebo and a stress scale improved. The reference point for label comparison.",
          "funding": "industry",
          "funder": "Ixoreal Biomedication (KSM-66 maker)"
        },
        {
          "id": "salve-2019-dose-range",
          "label": "Dose-ranging trial (Salve 2019)",
          "presetLabel": "Dose range",
          "amount": 250,
          "amountMax": 600,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "32021735"
          ],
          "effectDirection": "benefit",
          "note": "Three-arm trial comparing 250 and 600 mg per day of root extract. Perceived stress improved on both doses and cortisol on both, with the stronger signal at 600 mg. Establishes the studied range rather than one number.",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "sleep-and-weight-supplements",
        "finasteride-and-supplements",
        "nutrafol-vs-minoxidil"
      ],
      "guideUrls": [
        "https://supplementbrief.com/sleep-and-weight-supplements/",
        "https://supplementbrief.com/finasteride-and-supplements/",
        "https://supplementbrief.com/nutrafol-vs-minoxidil/"
      ],
      "shelf": {
        "registrySlug": "ashwagandha",
        "label": "Ashwagandha",
        "productCount": 2664,
        "medianPerServing": 200,
        "p25PerServing": 125,
        "p75PerServing": 470,
        "belowPrimaryFloorPct": 60,
        "abovePrimaryFloorPct": 31,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/ashwagandha/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/ashwagandha.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/ashwagandha/"
    },
    {
      "slug": "berberine",
      "version": "1",
      "displayName": "Berberine",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Berberine"
      ],
      "shelfComparable": true,
      "primaryFloorId": "lei-2026-adiposity",
      "trialFloors": [
        {
          "id": "lei-2026-adiposity",
          "label": "Adiposity RCT (Lei 2026, MASLD)",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "6 months",
          "evidenceLevel": "medium",
          "pmids": [
            "41543854"
          ],
          "n": 337,
          "effectDirection": "null",
          "note": "Diabetes-free adults with obesity and MASLD. 1 g/day berberine vs placebo for 6 months. Pre-specified primary endpoints (visceral adipose tissue, liver fat) did not differ from placebo. Excellent safety profile. Not GLP-1-level adiposity reduction.",
          "funding": "independent"
        },
        {
          "id": "weight-meta-1g",
          "label": "Weight meta-analyses (1 g/day and up)",
          "presetLabel": "Weight meta",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "8-12 weeks",
          "evidenceLevel": "medium",
          "palette": "research",
          "pmids": [
            "32379652",
            "32690176"
          ],
          "effectDirection": "secondary-only",
          "note": "Pooled body-weight estimates unstable across meta-analyses (−0.11 kg to −2.07 kg). Dose-response suggests ≥1 g/day. Indirect evidence; not mirtazapine-specific.",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "berberine-vs-ozempic",
        "berberine-with-semaglutide",
        "supplements-for-mirtazapine-weight-gain"
      ],
      "guideUrls": [
        "https://supplementbrief.com/berberine-vs-ozempic/",
        "https://supplementbrief.com/berberine-with-semaglutide/",
        "https://supplementbrief.com/supplements-for-mirtazapine-weight-gain/"
      ],
      "shelf": {
        "registrySlug": "berberine",
        "label": "Berberine",
        "productCount": 730,
        "medianPerServing": 400,
        "p25PerServing": 133,
        "p75PerServing": 500,
        "belowPrimaryFloorPct": 85,
        "abovePrimaryFloorPct": 6,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-24",
      "dosePageUrl": "https://supplementbrief.com/dose/berberine/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/berberine.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/berberine/"
    },
    {
      "slug": "chromium-picolinate",
      "version": "1",
      "displayName": "Chromium picolinate",
      "unit": "mcg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Chromium"
      ],
      "shelfComparable": true,
      "primaryFloorId": "cochrane-weight",
      "trialFloors": [
        {
          "id": "cochrane-weight",
          "label": "Cochrane weight review (pooled doses)",
          "presetLabel": "Cochrane weight",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "12-16 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "24293292"
          ],
          "n": 622,
          "effectDirection": "weak-benefit",
          "note": "Nine RCTs, 200–1000 µg/day chromium picolinate, 8–24 weeks. Body weight MD −1.1 kg (95% CI −1.7 to −0.4). Low-quality GRADE; debatable clinical relevance; no dose gradient.",
          "funding": "independent"
        },
        {
          "id": "pittler-sensitivity",
          "label": "Pittler 2003 sensitivity analysis",
          "presetLabel": "Pittler 2003",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "12-16 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "12664086"
          ],
          "effectDirection": "null",
          "note": "Removing one influential trial: −0.9 kg (95% CI −2.0 to 0.2), not statistically significant. Funnel plot asymmetry suggests publication bias.",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "supplements-for-mirtazapine-weight-gain"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-mirtazapine-weight-gain/"
      ],
      "shelf": {
        "registrySlug": "chromium-picolinate",
        "label": "Chromium picolinate",
        "productCount": 138,
        "medianPerServing": 200,
        "p25PerServing": 105,
        "p75PerServing": 500,
        "belowPrimaryFloorPct": 76,
        "abovePrimaryFloorPct": 20,
        "unit": "mcg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-24",
      "dosePageUrl": "https://supplementbrief.com/dose/chromium-picolinate/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/chromium-picolinate.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/chromium-picolinate/"
    },
    {
      "slug": "collagen-peptides",
      "version": "1",
      "displayName": "Collagen peptides (hydrolyzed)",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Collagen"
      ],
      "shelfComparable": true,
      "primaryFloorId": "verisol-skin",
      "trialFloors": [
        {
          "id": "verisol-skin",
          "label": "Verisol skin trials (branded peptide)",
          "presetLabel": "Verisol",
          "amount": 2.5,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "24401291",
            "23949208"
          ],
          "note": "Specific bioactive peptide preparation — generic 20 g powder is not equivalent evidence.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "generic-range",
          "label": "Generic hydrolyzed collagen (instrumental skin trials)",
          "presetLabel": "Generic collagen",
          "amount": 2.5,
          "amountMax": 10,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "note": "Pooled human skin trials often land in 2.5–10 g/day depending on preparation and endpoint.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "collagen-peptides-for-skin",
        "collagen-loose-skin-after-ozempic"
      ],
      "guideUrls": [
        "https://supplementbrief.com/collagen-peptides-for-skin/",
        "https://supplementbrief.com/collagen-loose-skin-after-ozempic/"
      ],
      "shelf": {
        "registrySlug": "collagen-peptides",
        "label": "Collagen peptides (hydrolyzed)",
        "productCount": 2583,
        "medianPerServing": 1.9,
        "p25PerServing": 0.3,
        "p75PerServing": 8.2,
        "belowPrimaryFloorPct": 54,
        "abovePrimaryFloorPct": 41,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/collagen-peptides/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/collagen-peptides.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/collagen-peptides/"
    },
    {
      "slug": "creatine",
      "version": "1",
      "displayName": "Creatine monohydrate",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Creatine"
      ],
      "shelfComparable": true,
      "primaryFloorId": "maintenance",
      "trialFloors": [
        {
          "id": "maintenance",
          "label": "Maintenance (postmenopausal + training meta-analyses)",
          "presetLabel": "Maintenance",
          "amount": 3,
          "amountMax": 5,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "42141930"
          ],
          "n": 608,
          "note": "Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor.",
          "effectDirection": "benefit",
          "funding": "mixed",
          "funder": "Alzchem (APC support)"
        },
        {
          "id": "bone-trial",
          "label": "Two-year bone trial dose (research)",
          "presetLabel": "Bone trial",
          "amount": 0.14,
          "unit": "g_per_kg",
          "frequency": "daily",
          "horizon": "2 years",
          "evidenceLevel": "limited",
          "pmids": [
            "37144634"
          ],
          "n": 237,
          "note": "~8–10 g at 60 kg. The primary endpoint failed — no effect on femoral neck, total hip or lumbar spine bone density over two years. Only secondary femoral-neck geometry (section modulus, buckling ratio) favoured creatine. This is a dose reference, not evidence that creatine builds bone.",
          "effectDirection": "null",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "creatine-for-women-over-40",
        "glp-1-companion-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/creatine-for-women-over-40/",
        "https://supplementbrief.com/glp-1-companion-supplements/"
      ],
      "shelf": {
        "registrySlug": "creatine",
        "label": "Creatine monohydrate",
        "productCount": 2893,
        "medianPerServing": 3,
        "p25PerServing": 1.3,
        "p75PerServing": 5,
        "belowPrimaryFloorPct": 48,
        "abovePrimaryFloorPct": 39,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/creatine/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/creatine.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/creatine/"
    },
    {
      "slug": "garlic",
      "version": "1",
      "displayName": "Garlic (aged extract)",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Garlic"
      ],
      "shelfComparable": true,
      "primaryFloorId": "ried-2018-age",
      "trialFloors": [
        {
          "id": "ried-2018-age",
          "label": "Aged garlic extract RCT (Ried 2018)",
          "presetLabel": "AGE 1.2 g",
          "amount": 1.2,
          "frequency": "daily",
          "horizon": "3 months",
          "evidenceLevel": "limited",
          "pmids": [
            "30619868"
          ],
          "effectDirection": "weak-benefit",
          "note": "1.2 g per day of Kyolic aged garlic extract, standardized to S-allylcysteine, for three months in adults with hypertension (the GarGIC trial). Moved blood pressure, arterial stiffness, and inflammation-related markers in a modest, part-of-the-population way; earlier AGE trials showed clearer blood-pressure effects in hypertensive subgroups. Honest read: a real but modest cardiovascular-risk candidate, in one studied form.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "how-to-read-supplement-label"
      ],
      "guideUrls": [
        "https://supplementbrief.com/how-to-read-supplement-label/"
      ],
      "shelf": {
        "registrySlug": "garlic",
        "label": "Garlic (aged extract)",
        "productCount": 366,
        "medianPerServing": 0.4,
        "p25PerServing": 0.1,
        "p75PerServing": 0.6,
        "belowPrimaryFloorPct": 99,
        "abovePrimaryFloorPct": 0,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/garlic/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/garlic.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/garlic/"
    },
    {
      "slug": "ginkgo-biloba",
      "version": "1",
      "displayName": "Ginkgo biloba (EGb 761)",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Ginkgo biloba"
      ],
      "shelfComparable": true,
      "primaryFloorId": "egb761-standard",
      "trialFloors": [
        {
          "id": "egb761-standard",
          "label": "Standardized EGb 761 extract (Kang 2002)",
          "presetLabel": "EGb 761",
          "amount": 120,
          "amountMax": 240,
          "frequency": "daily",
          "horizon": "8+ weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "12404672"
          ],
          "n": 37,
          "effectDirection": "null",
          "note": "120-240 mg per day of standardized EGb 761 (24% ginkgo flavone glycosides) is the extract standard nearly the whole evidence base was built on. Kang 2002, a small early RCT in 37 adults on fluoxetine or paroxetine, was positive; three later RCTs were null, which is why the effect direction here reads null. This floor is about the extract and dose standard, not a promise of effect.",
          "funding": "not-stated"
        },
        {
          "id": "aisd-900-historical",
          "label": "900 mg open-label pilots (historical only)",
          "presetLabel": "900 mg pilots",
          "amount": 900,
          "frequency": "daily",
          "horizon": "4-8 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "10784488",
            "9611693"
          ],
          "effectDirection": "null",
          "note": "Ashton 2000 and Cohen 1998, open-label pilots at 900 mg per day. Kept as historical context only: we do not present 900 mg as a target, and the controlled trials at the standard dose did not replicate the pilots.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "supplements-for-ssri-induced-ed"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-ssri-induced-ed/"
      ],
      "shelf": {
        "registrySlug": "ginkgo-biloba",
        "label": "Ginkgo biloba (EGb 761)",
        "productCount": 2688,
        "medianPerServing": 60,
        "p25PerServing": 30,
        "p75PerServing": 120,
        "belowPrimaryFloorPct": 66,
        "abovePrimaryFloorPct": 15,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/ginkgo-biloba/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/ginkgo-biloba.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/ginkgo-biloba/"
    },
    {
      "slug": "glucomannan",
      "version": "1",
      "displayName": "Glucomannan (konjac)",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Glucomannan"
      ],
      "shelfComparable": true,
      "primaryFloorId": "weight-meta-anchor",
      "trialFloors": [
        {
          "id": "weight-meta-anchor",
          "label": "Typical trial dose (anchor, not meta mean)",
          "presetLabel": "Trial anchor",
          "amount": 3,
          "frequency": "daily",
          "horizon": "8-12 weeks",
          "evidenceLevel": "limited",
          "n": 225,
          "effectDirection": "secondary-only",
          "note": "Zahra 2020 meta-analysis, six RCTs pooled −0.96 kg (95% CI −1.81 to −0.11), I²=88% (Obesity Medicine 2020;9:100276, doi:10.1016/j.obmed.2020.100276; journal is not PubMed-indexed, no PMID). Meta did not report pooled mean dose; 3 g/day before meals, split into 1 g doses three times daily, is typical in constituent trials and the EFSA minimum for the weight claim. Psyllium 10.8 g/day is the stronger fiber anchor in this guide.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "supplements-for-mirtazapine-weight-gain"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-mirtazapine-weight-gain/"
      ],
      "shelf": {
        "registrySlug": "glucomannan",
        "label": "Glucomannan (konjac)",
        "productCount": 219,
        "medianPerServing": 1,
        "p25PerServing": 0.2,
        "p75PerServing": 1.8,
        "belowPrimaryFloorPct": 96,
        "abovePrimaryFloorPct": 1,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-24",
      "dosePageUrl": "https://supplementbrief.com/dose/glucomannan/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/glucomannan.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/glucomannan/"
    },
    {
      "slug": "green-tea-egcg",
      "version": "1",
      "displayName": "Green tea extract (EGCG)",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Green tea"
      ],
      "shelfComparable": true,
      "primaryFloorId": "cochrane-pooled",
      "trialFloors": [
        {
          "id": "cochrane-pooled",
          "label": "Cochrane weight-loss review",
          "presetLabel": "Cochrane",
          "amount": 800,
          "frequency": "daily",
          "horizon": "12-13 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "23235664"
          ],
          "n": 1945,
          "effectDirection": "null",
          "note": "15 weight-loss trials. Small, statistically non-significant pooled effect; authors concluded not clinically important. Outside Japan MD −0.04 kg (95% CI −0.5 to 0.4).",
          "funding": "independent"
        },
        {
          "id": "dose-response-meta",
          "label": "Dose-response meta (Lin 2020)",
          "presetLabel": "Lin 2020",
          "amount": 800,
          "frequency": "daily",
          "horizon": "8-12 weeks",
          "evidenceLevel": "medium",
          "palette": "research",
          "pmids": [
            "32372444"
          ],
          "effectDirection": "secondary-only",
          "note": "Pooled −1.78 kg (95% CI −2.80 to −0.75). Waist reduction greater at ≥800 mg/day green tea preparations and duration <12 weeks. Heterogeneous extract types; part of effect is caffeine.",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "supplements-for-mirtazapine-weight-gain"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-mirtazapine-weight-gain/"
      ],
      "shelf": {
        "registrySlug": "green-tea-egcg",
        "label": "Green tea extract (EGCG)",
        "productCount": 5240,
        "medianPerServing": 100,
        "p25PerServing": 50,
        "p75PerServing": 250,
        "belowPrimaryFloorPct": 96,
        "abovePrimaryFloorPct": 3,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-24",
      "dosePageUrl": "https://supplementbrief.com/dose/green-tea-egcg/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/green-tea-egcg.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/green-tea-egcg/"
    },
    {
      "slug": "l-arginine",
      "version": "1",
      "displayName": "L-arginine",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Arginine"
      ],
      "shelfComparable": true,
      "primaryFloorId": "menafra-2022",
      "trialFloors": [
        {
          "id": "menafra-2022",
          "label": "Menafra 2022 (vasculogenic ED)",
          "presetLabel": "Menafra 2022",
          "amount": 6,
          "frequency": "daily",
          "horizon": "3 months",
          "evidenceLevel": "medium",
          "pmids": [
            "34973154"
          ],
          "n": 98,
          "note": "Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.",
          "effectDirection": "benefit",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "l-citrulline-vs-l-arginine-for-ed",
        "nitric-oxide-ed-supplements",
        "supplements-for-ssri-induced-ed"
      ],
      "guideUrls": [
        "https://supplementbrief.com/l-citrulline-vs-l-arginine-for-ed/",
        "https://supplementbrief.com/nitric-oxide-ed-supplements/",
        "https://supplementbrief.com/supplements-for-ssri-induced-ed/"
      ],
      "shelf": {
        "registrySlug": "l-arginine",
        "label": "L-arginine",
        "productCount": 3121,
        "medianPerServing": 0.8,
        "p25PerServing": 0.3,
        "p75PerServing": 1.5,
        "belowPrimaryFloorPct": 99,
        "abovePrimaryFloorPct": 1,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/l-arginine/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/l-arginine.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/l-arginine/"
    },
    {
      "slug": "l-citrulline",
      "version": "1",
      "displayName": "L-citrulline",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Citrulline"
      ],
      "shelfComparable": true,
      "primaryFloorId": "cormio-2011",
      "trialFloors": [
        {
          "id": "cormio-2011",
          "label": "Cormio 2011 pilot (mild ED)",
          "presetLabel": "Cormio 2011",
          "amount": 1.5,
          "frequency": "daily",
          "horizon": "1 month",
          "evidenceLevel": "limited",
          "pmids": [
            "21195829"
          ],
          "n": 24,
          "note": "Single-blind pilot; 95% CI not reported in primary paper.",
          "effectDirection": "benefit",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "l-citrulline-vs-l-arginine-for-ed",
        "nitric-oxide-ed-supplements",
        "supplements-for-ssri-induced-ed"
      ],
      "guideUrls": [
        "https://supplementbrief.com/l-citrulline-vs-l-arginine-for-ed/",
        "https://supplementbrief.com/nitric-oxide-ed-supplements/",
        "https://supplementbrief.com/supplements-for-ssri-induced-ed/"
      ],
      "shelf": {
        "registrySlug": "l-citrulline",
        "label": "L-citrulline",
        "productCount": 2818,
        "medianPerServing": 3,
        "p25PerServing": 1,
        "p75PerServing": 6,
        "belowPrimaryFloorPct": 32,
        "abovePrimaryFloorPct": 64,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/l-citrulline/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/l-citrulline.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/l-citrulline/"
    },
    {
      "slug": "maca",
      "version": "1",
      "displayName": "Maca root (Lepidium meyenii)",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Maca"
      ],
      "shelfComparable": true,
      "primaryFloorId": "aisd-women-3g",
      "trialFloors": [
        {
          "id": "aisd-women-3g",
          "label": "Antidepressant-induced sexual dysfunction, women",
          "presetLabel": "Women 3 g",
          "amount": 3,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "palette": "feminine",
          "pmids": [
            "25954318"
          ],
          "n": 42,
          "note": "Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "dose-finding-arms",
          "label": "Dose-finding pilot, 1.5 g arm failed",
          "presetLabel": "Dose-finding",
          "amount": 1.5,
          "amountMax": 3,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "18801111"
          ],
          "n": 16,
          "note": "Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it.",
          "effectDirection": "null",
          "funding": "not-stated"
        },
        {
          "id": "men-subjective-2400mg",
          "label": "Men with mild ED, subjective wellbeing",
          "presetLabel": "Men 2.4 g",
          "amount": 2.4,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "19260845"
          ],
          "n": 50,
          "note": "The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing.",
          "effectDirection": "secondary-only",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "supplements-for-ssri-induced-ed"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-ssri-induced-ed/"
      ],
      "shelf": {
        "registrySlug": "maca",
        "label": "Maca root (Lepidium meyenii)",
        "productCount": 1239,
        "medianPerServing": 0.3,
        "p25PerServing": 0.1,
        "p75PerServing": 0.6,
        "belowPrimaryFloorPct": 94,
        "abovePrimaryFloorPct": 4,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/maca/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/maca.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/maca/"
    },
    {
      "slug": "magnesium-l-threonate",
      "version": "1",
      "displayName": "Magnesium L-threonate",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Magnesium"
      ],
      "shelfComparable": true,
      "primaryFloorId": "cognition-sleep-2g",
      "trialFloors": [
        {
          "id": "cognition-sleep-2g",
          "label": "Cognition and sleep trial (compound weight)",
          "presetLabel": "Magtein 2 g",
          "amount": 2000,
          "frequency": "daily",
          "horizon": "6 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "41601871"
          ],
          "n": 100,
          "note": "2 g/day of branded Magtein in adults aged 18-45 reporting unsatisfying sleep. Overall cognition improved (NIH Total Cognition Composite, p = 0.043) along with reaction time, resting heart rate and HRV. Raven's matrices did not change, and neither did objective sleep from a wearable — only self-reported sleep-related impairment.",
          "effectDirection": "secondary-only",
          "funding": "industry",
          "funder": "Threotech Inc."
        }
      ],
      "guideSlugs": [
        "magnesium-forms-compared"
      ],
      "guideUrls": [
        "https://supplementbrief.com/magnesium-forms-compared/"
      ],
      "shelf": {
        "registrySlug": "magnesium-l-threonate",
        "label": "Magnesium L-threonate",
        "productCount": 152,
        "medianPerServing": 2000,
        "p25PerServing": 1000,
        "p75PerServing": 2000,
        "belowPrimaryFloorPct": 41,
        "abovePrimaryFloorPct": 14,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/magnesium-l-threonate/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/magnesium-l-threonate.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/magnesium-l-threonate/"
    },
    {
      "slug": "magnesium",
      "version": "1",
      "displayName": "Magnesium (elemental)",
      "unit": "mg",
      "doseKind": "elemental",
      "ingredientGroups": [
        "Magnesium"
      ],
      "shelfComparable": true,
      "primaryFloorId": "repletion-daily",
      "trialFloors": [
        {
          "id": "rda-female",
          "label": "Daily value (women)",
          "presetLabel": "Women DV",
          "amount": 320,
          "frequency": "daily",
          "evidenceLevel": "high",
          "palette": "feminine",
          "note": "FDA daily value reference — not a trial dose.",
          "funding": "not-stated"
        },
        {
          "id": "rda-male",
          "label": "Daily value (men)",
          "presetLabel": "Men DV",
          "amount": 420,
          "frequency": "daily",
          "evidenceLevel": "high",
          "palette": "maintenance",
          "note": "FDA daily value reference — not a trial dose.",
          "funding": "not-stated"
        },
        {
          "id": "repletion-daily",
          "label": "Form-comparison trial (elemental)",
          "presetLabel": "Form comparison",
          "amount": 300,
          "frequency": "daily",
          "horizon": "60 days",
          "evidenceLevel": "medium",
          "palette": "research",
          "pmids": [
            "14596323"
          ],
          "n": 46,
          "note": "300 mg elemental per day compared citrate, amino-acid chelate and oxide in healthy adults. The endpoint was absorption (urinary, serum, salivary magnesium), not a symptom — oxide did not separate from placebo.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "sleep-symptom",
          "label": "Bisglycinate sleep trial (elemental)",
          "presetLabel": "Sleep trial",
          "amount": 250,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "40918053"
          ],
          "n": 155,
          "note": "250 mg elemental as bisglycinate beat placebo on Insomnia Severity Index at week 4, but the effect was small (Cohen's d = 0.2) and concentrated in people with low dietary magnesium intake.",
          "effectDirection": "benefit",
          "funding": "industry",
          "funder": "Lopresti (nutraceutical funding)"
        }
      ],
      "guideSlugs": [
        "sleep-and-weight-supplements",
        "magnesium-forms-compared",
        "electrolytes-on-ozempic",
        "glp-1-companion-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/sleep-and-weight-supplements/",
        "https://supplementbrief.com/magnesium-forms-compared/",
        "https://supplementbrief.com/electrolytes-on-ozempic/",
        "https://supplementbrief.com/glp-1-companion-supplements/"
      ],
      "shelf": {
        "registrySlug": "magnesium",
        "label": "Magnesium (elemental)",
        "productCount": 27926,
        "medianPerServing": 100,
        "p25PerServing": 35,
        "p75PerServing": 200,
        "belowPrimaryFloorPct": 85,
        "abovePrimaryFloorPct": 12,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/magnesium/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/magnesium.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/magnesium/"
    },
    {
      "slug": "melatonin",
      "version": "1",
      "displayName": "Melatonin",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Melatonin"
      ],
      "shelfComparable": true,
      "primaryFloorId": "dswpd-half-mg",
      "trialFloors": [
        {
          "id": "dswpd-half-mg",
          "label": "Delayed sleep-wake phase disorder, 0.5 mg timed",
          "presetLabel": "Sletten 2018",
          "amount": 0.5,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "29912983"
          ],
          "n": 116,
          "note": "0.5 mg fast-release taken one hour before the desired bedtime, alongside behavioural sleep-wake scheduling in both arms. Sleep onset moved 34 minutes earlier (95% CI −60 to −8) and 52.8% improved on clinician rating vs 24.0% on placebo. The scheduling was part of the treatment — this is not a melatonin-alone result.",
          "effectDirection": "benefit",
          "referenceKind": "single-trial",
          "funding": "not-stated"
        },
        {
          "id": "phase-advance-low",
          "label": "Circadian phase advance, timing over dose",
          "presetLabel": "Mundey 2005",
          "amount": 0.3,
          "amountMax": 3,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "16295212"
          ],
          "n": 13,
          "note": "0.3 mg and 3.0 mg advanced circadian phase by the same amount. What predicted the size of the shift was when the dose was taken relative to dim-light melatonin onset (r² = 0.94), not how much was taken. Thirteen subjects.",
          "effectDirection": "benefit",
          "referenceKind": "single-trial",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "sleep-and-weight-supplements",
        "winter-blues-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/sleep-and-weight-supplements/",
        "https://supplementbrief.com/winter-blues-supplements/"
      ],
      "shelf": {
        "registrySlug": "melatonin",
        "label": "Melatonin",
        "productCount": 2662,
        "medianPerServing": 3,
        "p25PerServing": 2,
        "p75PerServing": 5,
        "belowPrimaryFloorPct": 3,
        "abovePrimaryFloorPct": 95,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/melatonin/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/melatonin.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/melatonin/"
    },
    {
      "slug": "nicotinamide-riboside",
      "version": "1",
      "displayName": "Nicotinamide riboside",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Nicotinamide riboside"
      ],
      "shelfComparable": true,
      "primaryFloorId": "nad-1000",
      "trialFloors": [
        {
          "id": "nad-1000",
          "label": "NAD+ elevation trial (1000 mg/day)",
          "presetLabel": "NAD+ trial",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "6 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "29599478"
          ],
          "n": 24,
          "note": "1000 mg/day for 6 weeks in a randomized double-blind crossover trial in healthy middle-aged and older adults; well-tolerated, elevated whole-blood NAD+. Cited in our urolithin A vs NMN guide, which covers the NAD+ booster shelf context.",
          "effectDirection": "secondary-only",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "urolithin-a-vs-nmn"
      ],
      "guideUrls": [
        "https://supplementbrief.com/urolithin-a-vs-nmn/"
      ],
      "shelf": {
        "registrySlug": "nicotinamide-riboside",
        "label": "Nicotinamide riboside",
        "productCount": 171,
        "medianPerServing": 100,
        "p25PerServing": 2,
        "p75PerServing": 250,
        "belowPrimaryFloorPct": 99,
        "abovePrimaryFloorPct": 1,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-27",
      "dosePageUrl": "https://supplementbrief.com/dose/nicotinamide-riboside/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/nicotinamide-riboside.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/nicotinamide-riboside/"
    },
    {
      "slug": "omega-3",
      "version": "1",
      "displayName": "Omega-3 (EPA + DHA combined)",
      "unit": "g",
      "doseKind": "epa_dha",
      "ingredientGroups": [
        "Fish Oil",
        "Omega-3 Fatty Acids"
      ],
      "shelfComparable": true,
      "primaryFloorId": "otc-inflammatory",
      "trialFloors": [
        {
          "id": "otc-inflammatory",
          "label": "OTC inflammatory-marker meta-analyses (EPA+DHA)",
          "presetLabel": "OTC EPA+DHA",
          "amount": 1,
          "amountMax": 2,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "24505395",
            "35914448"
          ],
          "note": "Active dose is EPA + DHA on the Supplement Facts panel — not total fish oil weight. This range is the span of doses pooled across 68 RCTs and 32 meta-analyses; neither review identifies a single threshold dose, and the CRP effect weakened above BMI 30.",
          "effectDirection": "benefit",
          "funding": "independent"
        },
        {
          "id": "epa-inflammatory-mdd",
          "label": "EPA dose-finding in inflammatory depression",
          "presetLabel": "EPA 4 g (MDD)",
          "amount": 4,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "36005883"
          ],
          "n": 45,
          "note": "EPA-only, in adults with major depression plus BMI over 25 and hs-CRP at or above 3 mg/L. Response was 64% vs 40% on placebo (Cohen d = 0.53) but not statistically significant, and the prespecified IL-6 and TNF endpoints were missed. A dose-finding signal in a narrow phenotype, not an established dose.",
          "effectDirection": "null",
          "funding": "not-stated"
        },
        {
          "id": "prescription-epa",
          "label": "REDUCE-IT (prescription icosapent ethyl)",
          "presetLabel": "REDUCE-IT",
          "amount": 4,
          "frequency": "daily",
          "evidenceLevel": "high",
          "pmids": [
            "30415628"
          ],
          "note": "Prescription purified EPA — not comparable to a standard fish oil capsule.",
          "effectDirection": "benefit",
          "funding": "industry",
          "funder": "Amarin Pharma"
        }
      ],
      "guideSlugs": [
        "omega-3-for-inflammation",
        "winter-blues-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/omega-3-for-inflammation/",
        "https://supplementbrief.com/winter-blues-supplements/"
      ],
      "shelf": {
        "registrySlug": "omega-3",
        "label": "Omega-3 (EPA + DHA combined)",
        "productCount": 7305,
        "medianPerServing": 0.6,
        "p25PerServing": 0.2,
        "p75PerServing": 0.9,
        "belowPrimaryFloorPct": 76,
        "abovePrimaryFloorPct": 19,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/omega-3/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/omega-3.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/omega-3/"
    },
    {
      "slug": "panax-ginseng",
      "version": "1",
      "displayName": "Korean red ginseng (Panax ginseng)",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Ginseng"
      ],
      "shelfComparable": true,
      "primaryFloorId": "krg-3g",
      "trialFloors": [
        {
          "id": "krg-3g",
          "label": "1000 mg three times daily (de Andrade 2007)",
          "presetLabel": "de Andrade 2007",
          "amount": 3,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "16855773"
          ],
          "n": 60,
          "note": "IIEF-5 rose from 16.4 to 21.0 against no change on placebo, and 66.6% reported improved erection. Testosterone, prolactin and cholesterol were unchanged, so this is not a hormonal mechanism. Single centre, mild to mild-moderate ED only.",
          "effectDirection": "benefit",
          "funding": "independent"
        },
        {
          "id": "krg-2700mg",
          "label": "900 mg three times daily (Hong 2002)",
          "presetLabel": "Hong 2002",
          "amount": 2.7,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "12394711"
          ],
          "n": 45,
          "note": "Double-blind crossover with an 8-week washout design. IIEF total and RigiScan penile tip rigidity both improved; 60% reported better erections. Explicitly published as a preliminary report.",
          "effectDirection": "benefit",
          "funding": "independent"
        },
        {
          "id": "cochrane-pooled",
          "label": "Cochrane pooled estimate (effect rated trivial)",
          "presetLabel": "Lee 2021",
          "amount": 3,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "palette": "research",
          "pmids": [
            "33871063"
          ],
          "n": 587,
          "note": "Nine RCTs, 587 men. Pooled IIEF-15 erectile-function difference was 3.52 points against a minimal clinically important difference of 4, and IIEF-5 was 2.39 points — Cochrane called the effect trivial at low-to-moderate certainty. The dose is real; the benefit at that dose is small on average.",
          "effectDirection": "null",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "panax-ginseng-for-ed",
        "how-to-read-supplement-label"
      ],
      "guideUrls": [
        "https://supplementbrief.com/panax-ginseng-for-ed/",
        "https://supplementbrief.com/how-to-read-supplement-label/"
      ],
      "shelf": {
        "registrySlug": "panax-ginseng",
        "label": "Korean red ginseng (Panax ginseng)",
        "productCount": 1377,
        "medianPerServing": 0.1,
        "p25PerServing": 0,
        "p75PerServing": 0.2,
        "belowPrimaryFloorPct": 100,
        "abovePrimaryFloorPct": 0,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/panax-ginseng/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/panax-ginseng.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/panax-ginseng/"
    },
    {
      "slug": "potassium",
      "version": "1",
      "displayName": "Potassium",
      "unit": "mg",
      "doseKind": "elemental",
      "ingredientGroups": [
        "Potassium"
      ],
      "shelfComparable": true,
      "primaryFloorId": "fda-otc-pill",
      "trialFloors": [
        {
          "id": "fda-otc-pill",
          "label": "US OTC pill limit (FDA)",
          "presetLabel": "OTC 99 mg",
          "amount": 99,
          "frequency": "daily",
          "horizon": "ongoing",
          "evidenceLevel": "high",
          "note": "The 99 mg elemental potassium limit per over-the-counter pill in the US exists because higher single-pill doses can injure the gut lining and because a bottle of high-dose pills is a hyperkalemia hazard in the wrong kidney. This entry is a ceiling, not a trial floor: potassium has no studied supplement dose, because its risk profile runs the other way.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "electrolytes-on-ozempic"
      ],
      "guideUrls": [
        "https://supplementbrief.com/electrolytes-on-ozempic/"
      ],
      "shelf": {
        "registrySlug": "potassium",
        "label": "Potassium",
        "productCount": 362,
        "medianPerServing": 475,
        "p25PerServing": 70,
        "p75PerServing": 750,
        "belowPrimaryFloorPct": 31,
        "abovePrimaryFloorPct": 68,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/potassium/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/potassium.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/potassium/"
    },
    {
      "slug": "protein",
      "version": "1",
      "displayName": "Dietary protein (complete)",
      "unit": "g",
      "doseKind": "daily_total",
      "ingredientGroups": [],
      "shelfComparable": false,
      "primaryFloorId": "glp1-weight-loss",
      "trialFloors": [
        {
          "id": "glp1-weight-loss",
          "label": "GLP-1 / weight-loss lean-mass context",
          "presetLabel": "GLP-1 context",
          "amount": 1.2,
          "amountMax": 1.6,
          "unit": "g_per_kg",
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "42560932"
          ],
          "note": "Multiply body weight (kg) by 1.2–1.6 for grams per day — not a fixed gram dose. Use the protein target calculator.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "example-70kg",
          "label": "Example at 70 kg (1.2–1.6 g/kg)",
          "presetLabel": "70 kg example",
          "amount": 84,
          "amountMax": 112,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "note": "Illustrative only — enter your weight in the protein calculator.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "protein-for-glp1",
        "glp-1-companion-supplements",
        "hair-loss-after-weight-loss"
      ],
      "guideUrls": [
        "https://supplementbrief.com/protein-for-glp1/",
        "https://supplementbrief.com/glp-1-companion-supplements/",
        "https://supplementbrief.com/hair-loss-after-weight-loss/"
      ],
      "shelf": null,
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/protein/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/protein.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/protein/"
    },
    {
      "slug": "psyllium",
      "version": "1",
      "displayName": "Psyllium husk fibre",
      "unit": "g",
      "doseKind": "compound",
      "ingredientGroups": [
        "Psyllium"
      ],
      "shelfComparable": true,
      "primaryFloorId": "weight-loss-meta",
      "trialFloors": [
        {
          "id": "constipation-meta",
          "label": "Chronic constipation meta-analysis (response threshold)",
          "presetLabel": "Constipation meta",
          "amount": 10,
          "amountMax": 30,
          "frequency": "daily",
          "horizon": "4+ weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "35816465",
            "3030900"
          ],
          "n": 1251,
          "note": "Sixteen RCTs in 1,251 chronically constipated adults. Symptom response was 66 percent on fibre versus 41 percent on control, and the subgroup analysis localized the effect to psyllium and pectin; stool frequency improved only above 10 g/day and only past four weeks. The classic dose-ranging study found 20 to 30 g/day beat 10 g on symptoms with dose-dependent stool weight gain, so titrate up from a teaspoon per dose instead of starting high.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "weight-loss-meta",
          "label": "Weight-loss meta-analysis (mean dose, before meals)",
          "presetLabel": "Weight-loss meta",
          "amount": 10.8,
          "frequency": "daily",
          "horizon": "4-5 months",
          "evidenceLevel": "medium",
          "pmids": [
            "37163454"
          ],
          "n": 354,
          "note": "Six RCTs in overweight and obese adults. Body weight fell 2.1 kg (95% CI −2.6 to −1.6), BMI 0.8 kg/m² and waist circumference 2.2 cm. 10.8 g/day is the mean dose across those trials, taken just before meals over a mean 4.8 months — the timing is part of the protocol, not a detail.",
          "effectDirection": "benefit",
          "funding": "industry",
          "funder": "employees of a commercial entity"
        }
      ],
      "guideSlugs": [
        "constipation-on-glp1",
        "supplements-for-mirtazapine-weight-gain",
        "glp-1-companion-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/constipation-on-glp1/",
        "https://supplementbrief.com/supplements-for-mirtazapine-weight-gain/",
        "https://supplementbrief.com/glp-1-companion-supplements/"
      ],
      "shelf": {
        "registrySlug": "psyllium",
        "label": "Psyllium husk fibre",
        "productCount": 762,
        "medianPerServing": 1,
        "p25PerServing": 0.3,
        "p75PerServing": 3,
        "belowPrimaryFloorPct": 98,
        "abovePrimaryFloorPct": 2,
        "unit": "g",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/psyllium/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/psyllium.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/psyllium/"
    },
    {
      "slug": "red-yeast-rice",
      "version": "1",
      "displayName": "Red yeast rice",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Red yeast rice"
      ],
      "shelfComparable": true,
      "primaryFloorId": "becker-2009",
      "trialFloors": [
        {
          "id": "becker-2009",
          "label": "Statin-intolerant RCT (Becker 2009)",
          "presetLabel": "Becker 2009",
          "amount": 3600,
          "frequency": "daily",
          "horizon": "24 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "19528562"
          ],
          "n": 62,
          "effectDirection": "benefit",
          "note": "1,800 mg twice per day (3,600 mg per day total) for 24 weeks in 62 adults with statin-intolerant dyslipidemia, randomized against placebo. LDL fell significantly. The effect is real because the active molecule is real: monacolin K is chemically identical to lovastatin, a statin-class drug effect delivered through a supplement label.",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "berberine-vs-ozempic"
      ],
      "guideUrls": [
        "https://supplementbrief.com/berberine-vs-ozempic/"
      ],
      "shelf": {
        "registrySlug": "red-yeast-rice",
        "label": "Red yeast rice",
        "productCount": 554,
        "medianPerServing": 900,
        "p25PerServing": 600,
        "p75PerServing": 1200,
        "belowPrimaryFloorPct": 100,
        "abovePrimaryFloorPct": 0,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-09-17",
      "dosePageUrl": "https://supplementbrief.com/dose/red-yeast-rice/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/red-yeast-rice.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/red-yeast-rice/"
    },
    {
      "slug": "saffron",
      "version": "1",
      "displayName": "Saffron (Crocus sativus) extract",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Saffron"
      ],
      "shelfComparable": true,
      "primaryFloorId": "aisd-men",
      "trialFloors": [
        {
          "id": "aisd-men",
          "label": "Fluoxetine-related sexual dysfunction, men",
          "presetLabel": "Men (AISD)",
          "amount": 30,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "22552758"
          ],
          "n": 30,
          "note": "15 mg twice daily in men whose depression was already stabilised on fluoxetine. Erectile function and intercourse satisfaction improved; orgasmic function, overall satisfaction and desire did not. Thirty completers in a single Iranian centre.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "aisd-women",
          "label": "Fluoxetine-related sexual dysfunction, women",
          "presetLabel": "Women (AISD)",
          "amount": 30,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "feminine",
          "pmids": [
            "23280545"
          ],
          "n": 34,
          "note": "Same 30 mg/day in women stabilised on fluoxetine 40 mg. Total FSFI, arousal, lubrication and pain improved; desire did not. Separate trial, separate instrument — do not read the men's result into this one or the reverse.",
          "effectDirection": "benefit",
          "funding": "not-stated"
        },
        {
          "id": "postpartum-vs-fluoxetine",
          "label": "Postpartum depression, saffron vs fluoxetine",
          "presetLabel": "Postpartum",
          "amount": 30,
          "frequency": "daily",
          "horizon": "6 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "27595298"
          ],
          "n": 64,
          "note": "15 mg twice daily against fluoxetine 20 mg twice daily in mild-to-moderate postpartum depression. There was no significant difference between arms, and complete response was 40.6% on saffron vs 50.0% on fluoxetine — an active-comparator trial with no placebo arm, so it does not establish that saffron beat nothing.",
          "effectDirection": "null",
          "funding": "not-stated"
        },
        {
          "id": "depression-meta",
          "label": "Depression meta-analyses (pooled)",
          "presetLabel": "Depression meta",
          "amount": 30,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "24299602",
            "31118846"
          ],
          "note": "Pooled saffron-vs-placebo effect was large but the confidence interval reached zero (SMD −0.86, 95% CI −1.73 to 0.00), and saffron did not differ from fluoxetine. Eight small trials, most from a single country. Treat 30 mg/day as the dose those trials used, not as a settled effective dose.",
          "effectDirection": "null",
          "funding": "industry",
          "funder": "Reserveage Organics"
        }
      ],
      "guideSlugs": [
        "supplements-for-ssri-induced-ed",
        "winter-blues-supplements"
      ],
      "guideUrls": [
        "https://supplementbrief.com/supplements-for-ssri-induced-ed/",
        "https://supplementbrief.com/winter-blues-supplements/"
      ],
      "shelf": {
        "registrySlug": "saffron",
        "label": "Saffron (Crocus sativus) extract",
        "productCount": 250,
        "medianPerServing": 30,
        "p25PerServing": 20,
        "p75PerServing": 89,
        "belowPrimaryFloorPct": 46,
        "abovePrimaryFloorPct": 39,
        "unit": "mg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/saffron/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/saffron.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/saffron/"
    },
    {
      "slug": "urolithin-a",
      "version": "1",
      "displayName": "Urolithin A",
      "unit": "mg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Urolithin A"
      ],
      "shelfComparable": false,
      "primaryFloorId": "atlas-branded",
      "trialFloors": [
        {
          "id": "atlas-branded",
          "label": "ATLAS trial, branded Mitopure",
          "presetLabel": "ATLAS 500 mg",
          "amount": 500,
          "amountMax": 1000,
          "frequency": "daily",
          "horizon": "4 months",
          "evidenceLevel": "limited",
          "pmids": [
            "35584623"
          ],
          "note": "Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.",
          "effectDirection": "secondary-only",
          "funding": "industry",
          "funder": "Amprocell (ATLAS sponsor)"
        },
        {
          "id": "older-adults-1g",
          "label": "Older adults, 1000 mg",
          "presetLabel": "Liu 2022",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "4 months",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "35050355"
          ],
          "n": 66,
          "note": "Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated.",
          "effectDirection": "null",
          "funding": "not-stated"
        },
        {
          "id": "safety-biology",
          "label": "Safety and mitochondrial gene signature",
          "presetLabel": "Andreux 2019",
          "amount": 500,
          "amountMax": 1000,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "32694802"
          ],
          "n": 60,
          "note": "Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers \"does oral urolithin A do anything in tissue\", not \"will I be stronger\".",
          "effectDirection": "null",
          "funding": "not-stated"
        },
        {
          "id": "endothelial-1g",
          "label": "Endothelial function trial (1000 mg)",
          "presetLabel": "da Costa Pinaffi-Langley 2026",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "palette": "research",
          "pmids": [
            "42853569"
          ],
          "n": 50,
          "note": "Double-blind placebo-controlled single-site trial in adults 40-64 with obesity; the primary endpoint, brachial artery flow-mediated dilation, did not separate from placebo, nor did secondary peripheral endothelial measures. Exploratory cerebrovascular hemodynamics moved in the urolithin group. Cited by our urolithin A vs NMN guide.",
          "effectDirection": "null",
          "funding": "independent"
        }
      ],
      "guideSlugs": [
        "urolithin-a-vs-nmn"
      ],
      "guideUrls": [
        "https://supplementbrief.com/urolithin-a-vs-nmn/"
      ],
      "shelf": null,
      "updatedDate": "2026-10-11",
      "dosePageUrl": "https://supplementbrief.com/dose/urolithin-a/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/urolithin-a.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/urolithin-a/"
    },
    {
      "slug": "vitamin-b12",
      "version": "1",
      "displayName": "Vitamin B12 (cobalamin)",
      "unit": "mcg",
      "doseKind": "compound",
      "ingredientGroups": [
        "Vitamin B12"
      ],
      "shelfComparable": true,
      "primaryFloorId": "repletion-oral",
      "trialFloors": [
        {
          "id": "repletion-oral",
          "label": "Oral repletion (deficiency confirmed)",
          "presetLabel": "Repletion",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "1 year",
          "evidenceLevel": "medium",
          "pmids": [
            "33513879",
            "29543316"
          ],
          "n": 90,
          "note": "1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight.",
          "effectDirection": "benefit",
          "funding": "independent"
        },
        {
          "id": "multivitamin-trap",
          "label": "Typical multivitamin (not therapeutic)",
          "presetLabel": "Multivitamin",
          "amount": 6,
          "amountMax": 25,
          "frequency": "daily",
          "evidenceLevel": "high",
          "note": "Illustrative floor only — not sufficient for metformin-associated deficiency repletion.",
          "funding": "not-stated"
        }
      ],
      "guideSlugs": [
        "metformin-b12-deficiency-which-form"
      ],
      "guideUrls": [
        "https://supplementbrief.com/metformin-b12-deficiency-which-form/"
      ],
      "shelf": {
        "registrySlug": "vitamin-b12",
        "label": "Vitamin B12 (cobalamin)",
        "productCount": 27296,
        "medianPerServing": 50,
        "p25PerServing": 9,
        "p75PerServing": 200,
        "belowPrimaryFloorPct": 90,
        "abovePrimaryFloorPct": 4,
        "unit": "mcg",
        "generatedAt": "2026-09-27T19:07:29.098Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/vitamin-b12/",
      "jsonUrl": "https://supplementbrief.com/data/v1/doses/vitamin-b12.json",
      "htmlUrl": "https://supplementbrief.com/data/v1/doses/vitamin-b12/"
    }
  ]
}
